Innovative Approaches to Managing Resistant/Uncontrolled Hypertension: Screening, Evaluation and Intervention​

This recording of a session led by experts, Keith Ferdinand and Naomi Fisher from the 20th Annual CMHC meeting, focuses on understanding the prevalence and impact of resistant hypertension in high-risk individuals, identifying contributing factors for early evaluation and treatment, and exploring recent FDA-approved therapies and emerging pharmacological options. It also highlights findings from pivotal clinical trials, real-world data on renal denervation, and national guideline recommendations. Additionally, it emphasizes the importance of individualized treatment strategies to optimize blood pressure control and reduce adverse outcomes in high-risk patients.

Target Audience

The educational design of this activity addresses the needs of U.S. based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), pharmacists, and other advanced practice providers.

Learning Objectives

After completing this activity, the participant should be better able to: 

  • Recognize the prevalence and burden of resistant hypertension in high-risk individuals.  

  • Evaluate comprehensive factors that may contribute to resistant hypertension in high-risk individuals as a means for early evaluation and treatment intensification.  

  • Summarize recent FDA approvals and emerging pharmacotherapies for resistant hypertension and results with renal denervation as highlighted in pivotal clinical trials and real-world registries and recommendations from national guidelines and scientific position statements.  

  • Identify comprehensive and individualized treatment options for high-risk individuals with resistant hypertension to optimize BP control and reduce the risk of adverse outcomes. 

Course summary
Available credit: 
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 CDE
  • 0.75 Participation
Course opens: 
01/27/2026
Course expires: 
01/27/2027
Rating: 
0

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, FPCNA (hon.)
Gerald S. Berenson Endowed Chair in Preventative Cardiology
Professor of Medicine
Tulane University School of Medicine  
New Orleans, LA  

 

Naomi D. L. Fisher MD
Director, Hypertension Service & Hypertension Innovation
Division of Endocrinology, Diabetes and Hypertension
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA 

ESTIMATED TIME TO COMPLETE ACTIVITY
0.75 hour

EDUCATIONAL GRANT SUPPORT

Supported by an independent medical educational grant from Medtronic, Inc.

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC).  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

Partners designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

Partners designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-058-H01-P Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DIETITIAN CONTINUING EDUCATION

This program offers 0.75 CPEUs for dietitians.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.75 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from January 27, 2026 through January 27, 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com

DISCLOSURES

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Ferdinand, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Amgen, Novartis, Boehringer Ingelheim, Medtronic, AstraZeneca 

Dr. Fisher, faculty for this educational activity, discloses the following:

  • Researcher: Recor Medical 

  • Consultant, Advisor, Speaker: Recor Medical, Alnylam, Astra Zeneca, Aktiia 

DISCLOSURE OF UNLABELED USE 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Available Credit

  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 CDE
  • 0.75 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.